|
Volumn 7, Issue 2, 2012, Pages 139-141
|
The king is dead (warfarin): Direct thrombin and factor Xa inhibitors: The next Diadochian War?
|
Author keywords
Antithrombotic; Cerebral hemorrhage; Cerebral infarction; Clinical trial; Ischemic stroke; Stroke
|
Indexed keywords
ANTIVITAMIN K;
APIXABAN;
DABIGATRAN;
KETOCONAZOLE;
LOW MOLECULAR WEIGHT HEPARIN;
PLACEBO;
RIVAROXABAN;
WARFARIN;
ARTICLE;
BLEEDING;
BRAIN HEMORRHAGE;
BRAIN ISCHEMIA;
EMBOLISM;
HEART ATRIUM FIBRILLATION;
HEART VALVE PROSTHESIS;
HUMAN;
INTERNATIONAL NORMALIZED RATIO;
KIDNEY DYSFUNCTION;
MORTALITY;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
RISK FACTOR;
STROKE;
SYSTEMIC EMBOLISM;
ANTICOAGULANTS;
ATRIAL FIBRILLATION;
BENZIMIDAZOLES;
BETA-ALANINE;
BRAIN ISCHEMIA;
CEREBRAL HEMORRHAGE;
FACTOR XA;
FIBRINOLYTIC AGENTS;
HUMANS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK;
RISK FACTORS;
STROKE;
THROMBIN;
WARFARIN;
|
EID: 84856199694
PISSN: 17474930
EISSN: 17474949
Source Type: Journal
DOI: 10.1111/j.1747-4949.2011.00739.x Document Type: Article |
Times cited : (8)
|
References (7)
|